ArticleMetabolic brain disease2025
Ferroptosis-inducing effects of cromolyn in microglia through NCOA4-mediated ferritinophagy.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Inhibition of NHE1 Overcomes Temozolomide-Resistance in Glioblastoma via ROS-AKT/ERK Axis-Mediated Autophagy Suppression.Journal of biochemical and molecular toxicology · 2026Article
- Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.Cancers · 2026Review
- Fenofibrate mitigates microglial activation by reprogramming lipid metabolism and inhibiting ferroptosis.Molecular and cellular biochemistry · 2026Article
- HMC3 revealed: how much do these "Microglia" really tell us?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cromolyn has anti-inflammatory and neuroprotective effects. However, its influence on microglial cell viability and death pathways remains largely unexplored. This study aimed to elucidate the cellular and molecular mechanisms underlying the effects of cromolyn exposure on microglial viability, with a particular focus on ferroptosis and ferritinophagy. HMC3 microglial cells were treated with cromolyn for 24, 48, and 72 h. Cell viability, nuclear morphology, cell cycle, MDA, GSH, and intracellular iron levels were assessed. Western blot analysis evaluated the expression of ferroptosis-related (GPX4, ACSL4, SLC7A11) and autophagy-associated (NCOA4, FTH1) proteins. Functional validation was performed using ferroptosis and autophagy inhibitors, and NCOA4-silencing. Cromolyn induced time- and dose-dependent cytotoxicity (IC₅₀ at 48 h = 9.4 µM), with prominent G0/G1 cell cycle arrest and nuclear abnormalities emerging at 48 h. At 72 h, excessive cell death limited mechanistic analyses. Cromolyn triggered ferroptosis via the GPX4-regulated pathway, evidenced by increased MDA, iron accumulation, and altered expression of GPX4, ACSL4, and SLC7A11. This ferroptotic response was mechanistically linked to NCOA4-mediated ferritinophagy, leading to GPX4 suppression and lipid peroxidation. NCOA4 knockdown rescued cell viability, restored FTH1 levels, and reduced lipid peroxidation. Our findings suggest, for the first time, that cromolyn may regulate microglial survival through an NCOA4-dependent ferritinophagy-ferroptosis axis. Given the dual roles of microglia in neuroinflammation and neurodegeneration, these data highlight both the therapeutic potential and risks of cromolyn in neurodegenerative disorders.
Indexed as
Identifiers
41182521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.